Avivagen Stock Performance
| VIVXF Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 2.93, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Avivagen will likely underperform. At this point, Avivagen has a negative expected return of -1.52%. Please make sure to confirm Avivagen's variance and kurtosis , to decide if Avivagen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Avivagen has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 664.2 K | |
| Total Cashflows From Investing Activities | -8707.00 |
Avivagen |
Avivagen Relative Risk vs. Return Landscape
If you would invest 0.36 in Avivagen on September 1, 2024 and sell it today you would lose (0.35) from holding Avivagen or give up 97.22% of portfolio value over 90 days. Avivagen is currently producing negative expected returns and takes up 12.1528% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Avivagen, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Avivagen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Avivagen's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Avivagen, and traders can use it to determine the average amount a Avivagen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.125
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VIVXF |
Estimated Market Risk
| 12.15 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.52 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Avivagen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Avivagen by adding Avivagen to a well-diversified portfolio.
Avivagen Fundamentals Growth
Avivagen Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Avivagen, and Avivagen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Avivagen Pink Sheet performance.
| Return On Asset | -0.95 | |||
| Operating Margin | (12.34) % | |||
| Current Valuation | 9.01 M | |||
| Shares Outstanding | 77.19 M | |||
| Price To Sales | 11.96 X | |||
| Revenue | 1.3 M | |||
| EBITDA | (4.68 M) | |||
| Cash And Equivalents | 494.81 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 1.4 M | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (4.6 M) | |||
| Earnings Per Share | (0.08) X | |||
| Total Asset | 3.48 M | |||
About Avivagen Performance
By analyzing Avivagen's fundamental ratios, stakeholders can gain valuable insights into Avivagen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Avivagen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Avivagen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Avivagen Inc., a life sciences company, focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada. Avivagen is traded on OTC Exchange in the United States.Things to note about Avivagen performance evaluation
Checking the ongoing alerts about Avivagen for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Avivagen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Avivagen generated a negative expected return over the last 90 days | |
| Avivagen has high historical volatility and very poor performance | |
| Avivagen has some characteristics of a very speculative penny stock | |
| Avivagen has a very high chance of going through financial distress in the upcoming years | |
| Avivagen has accumulated 1.4 M in total debt. Avivagen has a current ratio of 0.79, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Avivagen until it has trouble settling it off, either with new capital or with free cash flow. So, Avivagen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Avivagen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Avivagen to invest in growth at high rates of return. When we think about Avivagen's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 1.3 M. Net Loss for the year was (6.39 M) with profit before overhead, payroll, taxes, and interest of 534.34 K. | |
| Avivagen has accumulated about 494.81 K in cash with (4.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Avivagen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Avivagen's stock is overvalued or undervalued compared to its peers.
- Examining Avivagen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Avivagen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Avivagen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Avivagen's pink sheet. These opinions can provide insight into Avivagen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Avivagen Pink Sheet analysis
When running Avivagen's price analysis, check to measure Avivagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avivagen is operating at the current time. Most of Avivagen's value examination focuses on studying past and present price action to predict the probability of Avivagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avivagen's price. Additionally, you may evaluate how the addition of Avivagen to your portfolios can decrease your overall portfolio volatility.
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |